BlackRock, Inc. 13D and 13G filings for Apellis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 6,191,937 5.100% | 0 (Unchanged) | Filing |
| 2024-10-18 3:31 pm Purchase | 2024-09-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 6,191,937 5.100% | 444,753 (+7.74%) | Filing |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 5,747,184 4.900% | -1,957,010 (-25.40%) | Filing |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 7,704,194 7.000% | 1,838,482 (+31.34%) | Filing |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 5,865,712 6.100% | -149,236 (-2.48%) | Filing |
| 2021-02-05 07:51 am Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 6,014,948 7.900% | 1,257,443 (+26.43%) | Filing |